SRC and cancer: Moreover, Src inhibition by dasatinib or tirbanibulin disrupted mammosphere formation in CD96‐overexpressing tumor cells (Figure 6J and Figure S5E, Supporting Information) and Stat3 phosphorylation in BCSCs (Figure S5F, Supporting Information), supporting that CD96 can sustain cancer cell stemness via the Src‐Stat3 pathway.